HORMONE-POSITIVE HER2-NEGATIVE METASTATIC BREAST CANCER: DECISION MAKING IN REAL CLINICAL PRACTICE

HORMONE-POSITIVE HER2-NEGATIVE METASTATIC BREAST CANCER: DECISION MAKING IN REAL CLINICAL PRACTICE

Breast cancer (BC) is the most common female cancer and the first leading cause of cancer death in women. Luminal phenotypes represent about 70% of this disease. Treatment for metastatic hormone‑dependent HER2‑negative breast cancer in most cases involves various lines of endocrine therapy since the...

Full description

Saved in:
Bibliographic Details
Main Authors: L. Yu. Vladimirova, A. E. Storozhakova, T. A. Snezhko, L. K. Strakhova, N. A. Abramova, S. N. Kabanov, E. A. Kalabanova, N. Yu. Samaneva, Ya. V. Svetitskaya, A. V. Tishina
Format: Article
Language:Russian
Published: ANO "Perspective of oncology" 2020-06-01
Series:Южно-Российский онкологический журнал
Subjects:
metastatic breast cancer
hormone therapy
cyclin‑dependent kinases
ribocyclib
palbocyclib
abemacyclib
Online Access:https://www.cancersp.com/jour/article/view/59
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.cancersp.com/jour/article/view/59

Similar Items